{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:25:12Z","timestamp":1768314312806,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"OURG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00345-018-2196-8","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T08:31:03Z","timestamp":1517387463000},"page":"889-895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation"],"prefix":"10.1007","volume":"36","author":[{"given":"Ryuta","family":"Tanimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Saika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Ebara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Nasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Takamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Miyaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutomo","family":"Nasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyasu","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Kumon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"issue":"2","key":"2196_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"RJ Sylvester","year":"2016","unstructured":"Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, De Nunzio C, Okamura K, Kaasinen E, Solsona E, Ali-El-Dein B, Tatar CA, Inman BA, N\u2019Dow J, Oddens JR, Babjuk M (2016) Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 69(2):231\u2013244. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2015.05.050","journal-title":"Eur Urol"},{"issue":"29","key":"2196_CR2","doi-asserted-by":"publisher","first-page":"45479","DOI":"10.18632\/oncotarget.9991","volume":"7","author":"M Kang","year":"2016","unstructured":"Kang M, Jeong CW, Kwak C, Kim HH, Ku JH (2016) Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs. Oncotarget 7(29):45479\u201345488. \n                    https:\/\/doi.org\/10.18632\/oncotarget.9991","journal-title":"Oncotarget"},{"issue":"4","key":"2196_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00345-011-0691-2","volume":"29","author":"C Nunzio De","year":"2011","unstructured":"De Nunzio C, Carbone A, Albisinni S, Alpi G, Cantiani A, Liberti M, Tubaro A, Iori F (2011) Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. World J Urol 29(4):517\u2013521. \n                    https:\/\/doi.org\/10.1007\/s00345-011-0691-2","journal-title":"World J Urol"},{"issue":"4","key":"2196_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","volume":"55","author":"S Gudjonsson","year":"2009","unstructured":"Gudjonsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, Richthoff J, Hagberg G, Grabe M, Bendahl PO, Mansson W, Liedberg F (2009) Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55(4):773\u2013780. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2009.01.006","journal-title":"Eur Urol"},{"issue":"4","key":"2196_CR5","first-page":"220","volume":"3","author":"MR Barghi","year":"2006","unstructured":"Barghi MR, Rahmani MR, Hosseini Moghaddam SM, Jahanbin M (2006) Immediate intravesical instillation of mitomycin C after transurethral resection of bladder tumor in patients with low-risk superficial transitional cell carcinoma of bladder. Urol J 3(4):220\u2013224","journal-title":"Urol J"},{"issue":"9","key":"2196_CR6","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1002\/cncr.10496","volume":"94","author":"K Okamura","year":"2002","unstructured":"Okamura K, Ono Y, Kinukawa T, Matsuura O, Yamada S, Ando T, Fukatsu T, Ohno Y, Ohshima S, Nagoya University Urological Oncology G (2002) Randomized study of single early instillation of (2\u2033R)-4\u2032-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 94(9):2363\u20132368. \n                    https:\/\/doi.org\/10.1002\/cncr.10496","journal-title":"Cancer"},{"issue":"4","key":"2196_CR7","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S0022-5347(01)61606-9","volume":"161","author":"E Solsona","year":"1999","unstructured":"Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R (1999) Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 161(4):1120\u20131123","journal-title":"J Urol"},{"issue":"4","key":"2196_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00345-009-0502-1","volume":"28","author":"T Saika","year":"2010","unstructured":"Saika T, Tsushima T, Nasu Y, Miyaji Y, Saegusa M, Takeda K, Kumon H (2010) Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study. World J Urol 28(4):413\u2013418. \n                    https:\/\/doi.org\/10.1007\/s00345-009-0502-1","journal-title":"World J Urol"},{"issue":"3","key":"2196_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0022-5347(05)64556-9","volume":"168","author":"P Rajala","year":"2002","unstructured":"Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E, Finnbladder G (2002) Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study\u2013FinnBladder III long-term results. J Urol 168(3):981\u2013985. \n                    https:\/\/doi.org\/10.1097\/01.ju.0000026417.33622.7d","journal-title":"J Urol"},{"issue":"1","key":"2196_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.juro.2007.08.166","volume":"179","author":"I Berrum-Svennung","year":"2008","unstructured":"Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmang S (2008) A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 179(1):101\u2013105. \n                    https:\/\/doi.org\/10.1016\/j.juro.2007.08.166\n                    \n                   (discussion 105\u2013106)","journal-title":"J Urol"},{"issue":"5","key":"2196_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1046\/j.1464-410X.1997.00142.x","volume":"79","author":"B Ali-el-Dein","year":"1997","unstructured":"Ali-el-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A (1997) Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 79(5):731\u2013735","journal-title":"Br J Urol"},{"issue":"3","key":"2196_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1442-2042.2008.02235.x","volume":"16","author":"E Kikuchi","year":"2009","unstructured":"Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T (2009) Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999\u20132001 report from the Japanese Urological Association. Int J Urol 16(3):279\u2013286. \n                    https:\/\/doi.org\/10.1111\/j.1442-2042.2008.02235.x","journal-title":"Int J Urol"},{"issue":"3","key":"2196_CR13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.7164\/antibiotics.36.312","volume":"36","author":"S Kunimoto","year":"1983","unstructured":"Kunimoto S, Miura K, Takahashi Y, Takeuchi T, Umezawa H (1983) Rapid uptake by cultured tumor cells and intracellular behavior of 4\u2032-O-tetrahydropyranyladriamycin. J Antibiot (Tokyo) 36(3):312\u2013317","journal-title":"J Antibiot (Tokyo)"},{"issue":"7","key":"2196_CR14","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1046\/j.1464-410x.2000.00911.x","volume":"86","author":"Y Yamamoto","year":"2000","unstructured":"Yamamoto Y, Nasu Y, Saika T, Akaeda T, Tsushima T, Kumon H (2000) The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. BJU Int 86(7):802\u2013804","journal-title":"BJU Int"},{"issue":"3","key":"2196_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447\u2013461. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","journal-title":"Eur Urol"},{"issue":"1","key":"2196_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10156-010-0088-y","volume":"17","author":"T Maruyama","year":"2011","unstructured":"Maruyama T, Higuchi Y, Suzuki T, Qiu J, Yamamoto S, Shima H (2011) Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells. J Infect Chemother 17(1):11\u201316. \n                    https:\/\/doi.org\/10.1007\/s10156-010-0088-y","journal-title":"J Infect Chemother"},{"issue":"3","key":"2196_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000300571","volume":"85","author":"L Turkeri","year":"2010","unstructured":"Turkeri L, Tanidir Y, Cal C, Ozen H, Sahin H (2010) Comparison of the efficacy of single or double intravesical epirubicin instillation in the early postoperative period to prevent recurrences in non-muscle-invasive urothelial carcinoma of the bladder: prospective, randomized multicenter study. Urol Int 85(3):261\u2013265. \n                    https:\/\/doi.org\/10.1159\/000300571","journal-title":"Urol Int"},{"issue":"2","key":"2196_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","volume":"41","author":"W Oosterlinck","year":"2002","unstructured":"Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C, European Association of Urology Working Group on Oncological U (2002) Guidelines on bladder cancer. Eur Urol 41(2):105\u2013112","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-018-2196-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T08:39:01Z","timestamp":1548923941000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-018-2196-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["2196"],"URL":"https:\/\/doi.org\/10.1007\/s00345-018-2196-8","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"23 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors of this manuscript declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The OURG (Okayama, Japan) has been funded by several companies, including Meiji Seika Pharma Co., Ltd. This research was performed using self-funding from the OURG (Okayama, Japan), which is a non-profit organization that promotes and conducts clinical research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study was registered as UMIN C000000266 and approved by our institutional review board (IRB #05-1001).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Written informed consent was obtained from each patient based on local institutional guidelines.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}